Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respirato... (rely halts the synthesis of an essential...)

Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal

Date:7/1/2011

rely halts the synthesis of an essential protein. The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as the CFTR protein in nonsense mutation cystic fibrosis.

The development of ataluren has been supported by grants from Cystic Fibrosis Foundation Therapeutics, Inc. (the nonprofit affiliate of the Cystic Fibrosis Foundation); FDA's Office of Orphan Products Development; Muscular Dystrophy Association; National Center for Research Resources; National Heart, Lung, and Blood Institute; and Parent Project Muscular Dystrophy. The FDA and the European Commission have granted ataluren Orphan Drug status for the treatment of nonsense mutation cystic fibrosis and nonsense mutation Duchenne and Becker muscular dystrophy. The FDA has also granted ataluren Subpart E designation for expedited development, evaluation, and marketing for CF and dystrophinopathy and Fast Track designation for the development of treatment for nonsense mutation dystrophinopathy.

COLLABORATION WITH GENZYME

PTC Therapeutics has an exclusive collaboration with Genzyme Corporation for the development and commercialization of ataluren. PTC Therapeutics will commercialize ataluren in the United States and Canada, while Genzyme will commercialize the product in other regions of the world.

ABOUT CYSTIC FIBROSIS (CF)

CF is a life-threatening genetic disorder that causes serious lung infections and digestive complications. The predicted median age of survival for a person with CF is about 37 years. According to the Cystic Fibrosis Foundation, CF affects approximately 30,000 adults and children in the United States and nearly 70,000 people worldwide. Genetic testing is required to confirm a complete diagnosis and to determine if a patient's disease is caused by a nonsense mutation. It is estimated that nonsense mutations are the cause of CF in about 10 percent of patients in t
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis
2. PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
3. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
4. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
5. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
6. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
7. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
8. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
9. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
10. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
11. Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101

Post Your Comments:

(Date:5/22/2013)... and VANCOUVER, British Columbia , May ... ), a leader in the development of novel therapeutics to ... four trials of its investigational compounds, custirsen and OGX-427, will ... th Annual Meeting of the American Society of Clinical ... May 31 – June 4. Despite the ...

(Date:5/21/2013)... BEIJING, May 21, 2013 Concord Medical Services ... CCM ), a leading specialty hospital management solution ... and diagnostic imaging centers in China and the parent ... results for the first quarter ended March 31, 2013 ... , Total net revenue, which consists of net revenues ...

(Date:5/21/2013)... N.Y., May 21, 2013 Lakeland Industries, Inc. ... manufacturer of industrial protective clothing for industry, municipalities, ... and local levels, today announced that the Company ... a Senior Credit Facility subject to certain terms ... this financing. However, no assurances can be given ...

[0] OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting [0] Concord Medical Reports First Quarter 2013 Financial Results [0] Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results

... N.J., Nov. 9 Unwavering from its pursuit of ... climate, Lutronic, Inc., a leading developer of high quality ... fractional CO2 device priced at under $50,000. , ... to Lutronic,s fractional technology including scanning and stamping operation ...

... (NYSE Amex: KAD ), a leading provider of ... brand, has appointed Stephen Goldsmith to its Board of ... his resignation from the Board. , ... is the Daniel Paul Professor of Government and Director ...

Cached Medicine Technology:Lutronic(R) Unleashes the New MOSAIC CO2 2 Arcadia Resources Names Stephen Goldsmith to Board of Directors 2 Arcadia Resources Names Stephen Goldsmith to Board of Directors 3

Lutronic(R) Unleashes the New MOSAIC CO2 Arcadia Resources Names Stephen Goldsmith to Board of Directors

(Date:5/21/2013)... 21, 2013 Patients of Dr. Michael Shenk ... lost teeth due to gum disease and would like permanent ... disease treatment with laser gum surgery. Gum disease ... highest success rate out of all tooth replacement options. ... relatively new procedure cleared by the Food and Drug Administration ...

(Date:5/21/2013)... ContinuCare Home Health, Inc. recently received a ... Disability Services. After completing a four-day review of patient ... Health was found to have no deficiencies to be ... Department of Aging and Disability Services’ mission to provide ... and opportunities that are easily accessed in local ...

(Date:5/21/2013)... SOURCE XT one of the largest, post-approval transcatheter ... at EuroPCR 2013 show good clinical outcomes in routine ... all access approaches, valve sizes and delivery systems. , ... enrolled patients (mean age 81.5 years) undergoing TAVI with ... 17 countries between July 2010 and October 2011. Access ...

(Date:5/21/2013)... The In View series , a ... channels across the country, announces it has posted a ... producers of the series proudly bring audiences across the ... manufacturing industry, health-related companies, medical facilities and more. The ... in all parts of the United States, Canada and ...

(Date:5/21/2013)... Dallas, Texas (PRWEB) May 21, 2013 ... relationships. With the help of Texas Counseling’s Sexuality ... of communication, and the development of healthier habits ... group workshops available for both couples and individuals ... couples enhance their relationships and learn skills to ...

Breaking Medicine News(10 mins):Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2 Health News:ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services 2 Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2 Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2

[0] Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA [0] ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services [0] Post-approval TAVI registry shows high rates of device success at 1 year [0] In View hosted by Larry King Announces New Videos on its YouTube Channel [0] Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships

... Human Vaccine Institute today announced a collaboration and ... enable the rapid development of a vaccine and ... threat such as pandemic influenza. The team, composed ... of the National Institute of Allergy and Infectious ...

... HealthDay Reporter , WEDNESDAY, April 13 (HealthDay News) -- While ... the past few decades, this tragic outcome is still a reality ... a series of studies published online April 14 in The ... in the United States may be obesity, which can raise the ...

... of minor illnesses of astronauts in space may require special ... the space environment. That,s according to Dr. Putcha and ... published online in The AAPS Journal suggest that ... shorter shelf-life than they do on Earth. Pharmaceuticals used ...

... The judgments we make about the intimacy of ... brain chemical serotonin, reports a new study published in ... of serotonin activity had been lowered, rated couples in ... volunteers with normal serotonin activity. The approach involved giving ...

... (HealthDay News) -- Home safety devices greatly reduce the ... a new study. Researchers at Cincinnati Children,s Hospital ... newborns. One set of families had properly installed and ... cabinet locks, electrical outlet covers, smoke alarms, carbon monoxide ...

... By Amanda Gardner HealthDay Reporter , ... highlight the complexities hospitals face in controlling and containing ... to many antibiotics. While one study showed that ... Staphylococcus aureus (MRSA), the other found no ...

Cached Medicine News:Health News:Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines 2 Health News:Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines 3 Health News:Obesity, Disparities in Care Help Drive U.S. Stillbirths: Studies 2 Health News:Obesity, Disparities in Care Help Drive U.S. Stillbirths: Studies 3 Health News:Drug potency -- what happens in space? 2 Health News:Serotonin: A critical chemical for human intimacy and romance 2 Health News:With Safety Devices in Place, Kids' Injuries Decline: Study 2 Health News:Studies Highlight Challenge of Controlling Resistant Bacteria in Hospitals 2 Health News:Studies Highlight Challenge of Controlling Resistant Bacteria in Hospitals 3

Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines Obesity, Disparities in Care Help Drive U.S. Stillbirths: Studies Drug potency -- what happens in space?Serotonin: A critical chemical for human intimacy and romance With Safety Devices in Place, Kids' Injuries Decline: Study Studies Highlight Challenge of Controlling Resistant Bacteria in Hospitals

Fine tying forceps, standard with smooth jaws. For 7-0 to 9-0 sutures....

Maumenee tying forceps is straight with concave-convex jaws and has a round handle with guide pin. For 8-0 to 11-0 sutures....

Anis tying forcep is extra delicate with smooth jaws, curved. For 9-0 to 11-0 sutures....

McPherson titanium tying forceps which is 5 mm long, smooth jaws and straight. Used for 8-0 to 11-0 sutures....

Medicine Products:

Fine tying forceps Maumenee tying forceps Anis tying forceps McPherson tying forceps